Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
This office will be the central hub for all operations related to companies ethical pharmaceutical business
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
Stable profits, low leverage to keep credit profiles comfortable
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Subscribe To Our Newsletter & Stay Updated